Cargando…

The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children

BACKGROUND: The effect of sublingual Timothy grass immunotherapy tablet 2800 BAU (grass SLIT-T) has been evaluated in three North American trials in adults and children who have allergic rhinitis with or without conjunctivitis (AR/C). This paper examines the effects of grass SLIT-T in Canadians. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hébert, Jacques, Blaiss, Michael, Waserman, Susan, Kim, Harold, Creticos, Peter, Maloney, Jennifer, Kaur, Amarjot, Li, Ziliang, Nelson, Harold, Nolte, Hendrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4326370/ https://www.ncbi.nlm.nih.gov/pubmed/25685162 http://dx.doi.org/10.1186/1710-1492-10-53

Ejemplares similares

Efficacy and safety of MK-7243: a grass allergy sublingual immunotherapy tablet evaluated in Canadian adults and children
por: Hébert, Jacques, et al.
Publicado: (2014)

Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis
por: Kim, Harold, et al.
Publicado: (2014)

Efficacy and safety of standardized short ragweed sublingual immunotherapy tablet (SLIT-T) treatment in Canadian subjects with ragweed pollen-induced rhinitis with or without conjunctivitis
por: Blaiss, Michael, et al.
Publicado: (2014)

Efficacy of Timothy grass allergy immunotherapy tablet (AIT) treatment in Canadian children and adults with grass pollen-induced allergic rhinoconjunctivitis (ARC)
por: Hebert, Jacques, et al.
Publicado: (2011)

The effect of the ragweed sublingual immunotherapy tablet MK-3641 on rescue medication use
por: Gawchik, Sandra, et al.
Publicado: (2014)

Efficacy of short-ragweed sublingual immunotherapy tablet MK-3641 in monosensitized and polysensitized subjects
por: Bernstein, David I, et al.
Publicado: (2014)

A practical guide to prescribing sublingual immunotherapy tablets in North America for pediatric allergic rhinoconjunctivitis: an injection-free allergy immunotherapy option
por: Blaiss, Michael, et al.
Publicado: (2023)

Magnitude of changes in patient symptom and medication scores in grass allergy immunotherapy trials: dependency on levels of pollen exposure
por: Nolte, Hendrik, et al.
Publicado: (2014)

The efficacy and safety of the short ragweed sublingual immunotherapy tablet MK-3641 is similar in asthmatic and nonasthmatic subjects treated for allergic rhinitis with/without conjunctivitis
por: Maloney, Jennifer, et al.
Publicado: (2014)

4 The Risk of Severe Treatment Related Adverse Events is Significantly Lower in Children Compared to Adults When Treated With Standardized Timothy Grass Allergy Immunotherapy Tablets: Post Hoc Analysis of 7 Clinical Trials
por: Andersen, Jens Strodl, et al.
Publicado: (2012)

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study
por: Reiber, Rainer, et al.
Publicado: (2016)

161 Efficacy and Safety of 300IR 5-Grass Pollen Sublingual Allergen Immunotherapy Tablets in us Adults With Grass-Pollen Allergic Rhinoconjunctivitis
por: Cox, Linda, et al.
Publicado: (2012)

Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis
por: Ellis, Anne K., et al.
Publicado: (2021)

Minimization of ragweed allergy immunotherapy costs through use of the sublingual immunotherapy tablet in Canadian children with allergic rhinoconjunctivitis
por: Ellis, Anne K., et al.
Publicado: (2023)

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure
por: Durham, S R, et al.
Publicado: (2014)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

Sublingual immunotherapy: World Allergy Organization position paper 2013 update
por: Canonica, Giorgio Walter, et al.
Publicado: (2014)

Current status of sublingual immunotherapy in the United States
por: Elenburg, Shelby, et al.
Publicado: (2014)

Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI)
por: Leith, Eric, et al.
Publicado: (2006)

Development of a sublingual allergy vaccine for grass pollinosis
por: Frati, Franco, et al.
Publicado: (2010)

176 Sublingual Immunotherapy for Grass Pollen Allergy in Children: A Systematic Review and Meta-Analysis
por: Bryson, Rebecca
Publicado: (2012)

Plant Food Allergy Improvement after Grass Pollen Sublingual Immunotherapy: A Case Series
por: Furci, Fabiana, et al.
Publicado: (2021)

Satisfaction and quality of life of allergic patients following sublingual five-grass pollen tablet immunotherapy in Spain
por: Antolín-Amerigo, Darío, et al.
Publicado: (2017)

Sensitization to timothy grass pollen allergenic molecules in children
por: Scaparrotta, Alessandra, et al.
Publicado: (2013)

Sensitization Profiles of Timothy Grass Pollen in Northern China
por: Xu, Yingyang, et al.
Publicado: (2021)

Allergen Release Profiles of Fast-Dissolving Freeze-Dried Orodispersible Sublingual Allergy Immunotherapy Tablets
por: Yamamoto, Takashi, et al.
Publicado: (2022)

Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(®)) in children
por: Ronaldson, Sarah, et al.
Publicado: (2014)

Oral and sublingual immunotherapy for food allergy
por: Le, Uyenphuong H, et al.
Publicado: (2014)

Determining the minimal important differences in the RQLQ score with grass and tree allergy immunotherapy versus placebo in adults with moderate‐to‐severe allergy
por: Blaiss, Michael S., et al.
Publicado: (2022)

Implementation of pre-seasonal sublingual immunotherapy with a five-grass pollen tablet during optimal dosage assessment
por: Horak, F, et al.
Publicado: (2009)

Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in patients with different clinical profiles of allergic rhinoconjunctivitis
por: Malling, H-J, et al.
Publicado: (2009)

A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy
por: Ciprandi, Giorgio
Publicado: (2015)

Technical and clinical validation of the Allergen BioCube(®) for timothy grass
por: Angjeli, Endri, et al.
Publicado: (2017)

Lipid Mediators From Timothy Grass Pollen Contribute to the Effector Phase of Allergy and Prime Dendritic Cells for Glycolipid Presentation
por: González Roldán, Nestor, et al.
Publicado: (2019)

Specific immunotherapy by the sublingual route for respiratory allergy
por: Incorvaia, Cristoforo, et al.
Publicado: (2010)

Sublingual immunotherapy for pediatric patients with mite allergies
por: Kajiume, Teruyuki
Publicado: (2022)

Effect of Pollen-Specific Sublingual Immunotherapy on Oral Allergy Syndrome: An Observational Study
por: Bergmann, Karl-Christian, et al.
Publicado: (2008)

Sublingual Immunotherapy with a Five-Grass Pollen Tablet in Adult Patients with Allergic Rhinitis: An Open, Prospective, Noninterventional, Multicenter Study
por: Pfaar, Oliver, et al.
Publicado: (2015)

208 Compliance and Persistence to Grass Immunotherapy Treatment is Comparable for Allergy Immunotherapy Tablets and Subcutaneous Immunotherapy: A Swedish Registry Study
por: Andreasen, Jakob Nørgaard, et al.
Publicado: (2012)

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study
por: Schwab, Jan-Alexander, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_moom2ci5m24o8ioboemhqorhrc